Management of Patients with Chronic Heart Failure and Diabetes Mellitus

Management of Patients with Chronic Heart Failure and Diabetes Mellitus

Chronic heart failure (CHF) occurs in 4.3-28% of patients with diabetes mellitus and is most often associated with the presence of coronary heart disease, arterial hypertension and the direct adverse effects of insulin-resistance, hyperinsulinemia and hyperglycemia on the myocardium. Diabetes mellit...

Full description

Bibliographic Details
Main Authors:	E. V. Reznik, T. L. Nguyen, G. N. Golukhov
Format:	Article
Language:	English
Published:	Столичная издательская компания 2021-05-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	chronic heart failure diabetes mellitus left ventricular ejection fraction pharmacotherapy angiotensin receptor-neprilysin inhibitor sglt-2 sodium-glucose cotransporter-2
Online Access:	https://www.rpcardio.online/jour/article/view/2445

Similar Items

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
by: Yuling Yan, et al.
Published: (2021-06-01)

Diabetes Mellitus and Heart Failure
by: Wun-Zhih Siao, et al.
Published: (2022-10-01)

Reshaping Treatment of Heart Failure with Preserved Ejection Fraction
by: Nikolaos Karamichalakis, et al.
Published: (2022-06-01)

The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder
by: Pankaj V. Jariwala, et al.
Published: (2022-10-01)

Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
by: Julie Hempel Larsen, et al.
Published: (2023-02-01)

Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data
by: Alvaro Alonso, et al.
Published: (2024-03-01)

Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy
by: Wei-Chieh Lee, et al.
Published: (2023-04-01)

Prescribing patterns of SGLT-2 inhibitors for patients with heart failure: A two-center analysis
by: Teja Chakrala, et al.
Published: (2023-04-01)

Emerging concepts in heart failure management and treatment: focus on current guideline-directed medical therapy for heart failure with reduced ejection fraction
by: Oscar Eduardo Ospina González, et al.
Published: (2023-01-01)

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials
by: Luxi Ji, et al.
Published: (2023-03-01)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
by: Sheldon E. Litwin, et al.
Published: (2022-12-01)

Sodium-Glucose Cotransporter-2 Inhibitors-from the Treatment of Diabetes to Therapy of Chronic Heart Failure
by: Dominik Kurczyński, et al.
Published: (2022-07-01)

Editorial: Diabetes and heart failure: basic, translational, and clinical research
by: Laurent Metzinger, et al.
Published: (2023-05-01)

The Impact of Chronic Heart Failure Treatment on Glycemic Variability in Patients without Diabetes Mellitus
by: Georgiy B. Mankovsky, et al.
Published: (2023-09-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
by: Fumitaka Soga, et al.
Published: (2018-10-01)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
by: In-Chang Hwang, et al.
Published: (2020-05-01)

Heart Failure in Patients with Chronic Kidney Disease
by: Andrew Xanthopoulos, et al.
Published: (2023-09-01)

Chronic heart failure: advances in pharmacological treatment and future perspectives
by: Gabriela M. Kuster, et al.
Published: (2019-03-01)

The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients
by: Ji‐Hye Oh, et al.
Published: (2022-08-01)

Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
by: Hidekatsu Fukuta, et al.
Published: (2022-10-01)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
by: Juexing Li, et al.
Published: (2022-09-01)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
by: Hallinen T, et al.
Published: (2023-01-01)

Long‐term impact of angiotensin receptor‐neprilysin inhibitor based on short‐term treatment response in heart failure
by: Hyuk Kyoon Park, et al.
Published: (2023-12-01)

Is Sacubitril/Valsartan Able to Change the Timing for Implantation of Cardiac Devices in Heart Failure with Reduced Ejection Fraction?
by: Marta Afonso Nogueira, et al.
Published: (2022-08-01)

Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors
by: Weronika Frąk, et al.
Published: (2023-07-01)

Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium
by: Christos Kourek, et al.
Published: (2024-03-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction
by: April F. Mohanty, et al.
Published: (2021-10-01)

Association between Dapagliflozin, Cardiac Biomarkers and Cardiac Remodeling in Patients with Diabetes Mellitus and Heart Failure
by: Andrew Xanthopoulos, et al.
Published: (2023-08-01)

Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects
by: Donghyun Kim, et al.
Published: (2022-11-01)

Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon
by: Fabiana Lucà, et al.
Published: (2024-02-01)

Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure
by: Alex Ali Sayour, et al.
Published: (2020-09-01)

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with a Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials
by: Yake Lou, et al.
Published: (2022-10-01)

Sodium-glucose cotransporter type 2 inhibitors in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis
by: Evgeny M. Mezhonov, et al.
Published: (2023-04-01)

Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
by: Daisuke Matsutani, et al.
Published: (2018-05-01)

Cost effectiveness analyses of pharmacological treatments in heart failure
by: Audrey Huili Lim, et al.
Published: (2022-09-01)

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling
by: Seul-Gee Lee, et al.
Published: (2022-09-01)